AMRN
Amarin Corporation plc·Healthcare
14.48
2.030%(−0.30)
Market ClosedLast Updated: — ET
52W L: $8.3252W H: $20.90
AMRN NEWS
fool.com
Mar 7
Here's Why I Wouldn't Touch Amarin With a 10‑Foot Pole Given Its Patent and Competition Risks
Amarin has one drug, and it has lost key patent protections. The company is cutting costs in an effort to generate positive cash flow.
zacks.com
Mar 5
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know
Amarin shares surge 37.7% in a year as restructuring, cost cuts and expanding Vazkepa partnerships for international growth fuel optimism.
fool.com
Mar 3
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Amarin's results depend on a single medicine that is already facing generic competition. By contrast, Novartis has a deep lineup, plenty of growth products, and a solid dividend program.
defenseworld.net
Feb 28
Amarin Q4 Earnings Call Highlights
Amarin (NASDAQ: AMRN) executives told investors that 2025 marked a "substantial achievement" year as the company advanced a strategic pivot toward a more partnered international commercial model and executed a global restructuring aimed at lowering its operating expense base. On the company's fourth-quarter and full-year 2025 earnings call, management highlighted a new long-term agreement with Recordati
zacks.com
Feb 26
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss
AMRN swings to Q4 profit and beats estimates, but revenues decline 21% as Vascepa sales slide and shares fall 9% on the mixed results.
seekingalpha.com
Feb 25
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q4 2025 Earnings Call Transcript
